MOUNTAINSIDE, N.J., Sept. 25, 2018 /PRNewswire/ -- Androvia LifeSciences has announced the publication of a recent prospective study that demonstrates men who had a normal score on a new fertility test, Cap-Score™, had a fourfold increase in pregnancies during the first attempt compared to men with a low score. The study was published in the journal, Molecular Reproduction and Development, a Wiley publication. Equally important, clinical outcomes as measured by pregnancies in couples having difficulty conceiving, clearly show that Cap-Score is a reliable predictor of a man's probability of generating a pregnancy. A man's fertility can now be measured and ranked using Cap-Score. There are no such tests readily available to men and clinicians.
Experience the interactive Multichannel News Release here: https://www.multivu.com/players/English/8407651-androvia-lifesciences-cap-score-fertility-test/
"This innovative test appears to be a promising method for assessing the male partner's potential for achieving a pregnancy; it may enhance our ability to provide more efficient and individualized treatment paradigms for couples with male infertility," said Zev Rosenwaks, M.D., Director and Physician-in-Chief, Ronald O. Perelman and Claudia Cohen Center for Reproductive Medicine.
The results from this proprietary male fertility test provide a solution for many couples, including those who are struggling to conceive and become pregnant. In fact, millions of men seek assistance for fertility each year. Remarkably, more than 50% of male infertility is diagnosed as unexplained by current, inadequate methods. Understanding a man's probability to generate a pregnancy will help clinicians counsel couples with personalized guidance to shorten their journey to parenthood saving time, emotional distress and money. Whether the couple has decided to delay parenthood or the man is diagnosed with male factor infertility, Cap-Score can assist the couple and the clinician in achieving pregnancy.
"We now have a tool to better assess male fertility. We no longer need to rely solely on a semen analysis. The addition of Cap-Score to the clinical evaluation of male fertility offers a functional measure that will help clinicians better counsel couples on how much intervention may or may not be needed," said Eric Seaman, M.D., of New Jersey Urology, a leading practitioner of male reproductive medicine.
Cap-Score represents a breakthrough technology that has shifted the focus of understanding a man's fertility from descriptive measures found with a semen analysis to a functional measure that analyzes the biological process within the sperm cell controlling fertilization. This biological process, known as capacitation, cannot be measured by a semen analysis, but can be quantified by Cap-Score. The published study shows Cap-Score is the best predictor of a man's fertility.
"Tests of sperm function that provide clinically useful information to help optimize couples path to parenthood are needed and we are optimistic after reviewing the data that Cap-Score has the potential to be a significant contributor in this arena. We are fortunate to be one of the select reproductive centers to currently offer this new tool to help our couples with possible or established male factor infertility fulfill their dreams of establishing a family" said Natan Bar-Chama, M.D., Director of the Center of Male Reproductive Health at RMA of New York.
In the study, Cap-Score and clinical pregnancy outcomes were analyzed for 91 couples. Based on Cap-Score, men were separated into two groups. The newly published data showed that men with normal Cap-Scores generated four times the number of pregnancies in the first attempt than men with low Cap-Scores. The data also yielded dramatic and consistently high pregnancy rates in the second and third attempts for men with normal scores.
For access to the complete publication please visit: https://onlinelibrary.wiley.com/doi/10.1002/mrd.23057.
"The ability to determine the man's probability of generating a pregnancy is a substantial advance for all couples when planning their families. This is particularly important when childbirth is being delayed resulting in an increased likelihood of encountering potential problems," said Gianpiero Palermo, M.D., Ph.D., Director of Assisted Fertilization and the Andrology Laboratory at the Ronald O. Perelman and Claudia Cohen Center for Reproductive Medicine at Weill Cornell Medicine. Dr. Palermo is a member of Androvia LifeSciences' Clinical Advisory Team.
"Cap-Score also addresses the many questions about what may have a positive or negative effect on a man's fertility. Similarly, since we now know how to measure the process that controls fertility within the sperm cell, we also may have the foundation for a novel approach to male contraception. This technology can also be applied to important aspects of animal health care and particularly the breeding of livestock. The benefits are quite expansive," said Michael V. Novinski, CEO of Androvia LifeSciences.
Androvia LifeSciences is a NY-based, privately held company focused on developing new diagnostics that provide a higher level of patient management of male fertility for use by clinicians to counsel couples. The company's objective is to understand male fertility at its most fundamental level – how it occurs, how it's measured, and how it can be applied to improve outcomes.
The company operates at the highest standard of laboratories which is CLIA compliant, New Jersey DOH approved, certified by the College of American Pathology and licensed by New York State as both a facility and as an approved Laboratory Test. Cornell University has licensed the Cap-Score technology to Androvia LifeSciences for development into a commercially practical diagnostic assay. The company has analyzed over 1300 men since late 2016, has published five peer reviewed articles and has made multiple invited presentations on its cutting-edge technology. Couples and clinicians who are interested in learning more about the Cap-Score and the probability of a man's ability to generate a pregnancy can click here or visit www.androvialife.com. The Cap-Score test is currently available to physicians and couples.
SOURCE Androvia LifeSciences